Evidence map›Paper›PMID 37278391›Full record

ArticleAdvanced healthcare materials2023

Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine.

Ben S Ou, Olivia M Saouaf, Jerry Yan, Theodora U J Bruun, Julie Baillet, Xueting Zhou, Neil P King, Eric A Appel

Open access · hybridAbstract read
In one paragraph

Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Hydrogel applications: a promising frontier in pneumonia therapy.Frontiers in bioengineering and biotechnology · 2025
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Ben S OuDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0002-0539-5166
Olivia M SaouafDepartment of Materials Science & Engineering, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0002-5117-7127
Jerry YanDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0001-8278-1354
Theodora U J BruunDepartment of Biochemistry, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Julie BailletDepartment of Materials Science & Engineering, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0003-4670-5762
Xueting ZhouDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Neil P KingDepartment of Biochemistry, University of Washington, Seattle, WA, 98109, USA.
Eric A AppelDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0002-2301-7126
Stanford University · USStanford Medicine · USCentre National de la Recherche Scientifique · FRUniversity of Washington · US

Funding

Acquisition of a 300 kV Electron Microscope for Structural BiologyS10OD021600 · OD · STANFORD UNIVERSITY · PI CHIU, WAH · 2016 to 2016
$2.0M
NIH HHS S10 OD021600
6 · The paper itself

Abstract

Most vaccines require several immunizations to induce robust immunity, and indeed, most SARS-CoV-2 vaccines require an initial two-shot regimen followed by several boosters to maintain efficacy. Such a complex series of immunizations unfortunately increases the cost and complexity of populations-scale vaccination and reduces overall compliance and vaccination rate. In a rapidly evolving pandemic affected by the spread of immune-escaping variants, there is an urgent need to develop vaccines capable of providing robust and durable immunity. In this work, a single immunization SARS-CoV-2 subunit vaccine is developed that can rapidly generate potent, broad, and durable humoral immunity. Injectable polymer-nanoparticle (PNP) hydrogels are leveraged as a depot technology for the sustained delivery of a nanoparticle antigen (RND-NP) displaying multiple copies of the SARS-CoV-2 receptor-binding domain (RBD) and potent adjuvants including CpG and 3M-052. Compared to a clinically relevant prime-boost regimen with soluble vaccines formulated with CpG/alum or 3M-052/alum adjuvants, PNP hydrogel vaccines more rapidly generated higher, broader, and more durable antibody responses. Additionally, these single-immunization hydrogel-based vaccines elicit potent and consistent neutralizing responses. Overall, it is shown that PNP hydrogels elicit improved anti-COVID immune responses with only a single administration, demonstrating their potential as critical technologies to enhance overall pandemic readiness.

Indexed as

COVID-19COVID-19 VaccinesAlum CompoundsAntibodies, ViralHumansHydrogelsImmunity, HumoralImmunizationSARS-CoV-2VaccinationVaccines, SubunitAlum Compoundsaluminum sulfateAntibodies, ViralCOVID-19 VaccinesHydrogelsVaccines, SubunitCOVID-19hydrogelsimmunoengineeringSARS-CoV-2vaccines

Identifiers

PMID37278391
PMCPMC12967408
OpenAlexW4379508142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.